In vitro anticancer activity screening of Iridaceae plant extracts

Olha Mykhailenko1, Roman Lesyk2,3, Nataliya Finiuk3, Rostyslav Stoika4, Tetyana Yushchenko4, Anna Ocheretniuk5, Valentyna Vaschuk5, Volodymyr Mishchenko6, Victoriya Georgiyants7

1Department of Botany, National University of Pharmacy, Kharkiv, Ukraine.
2Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
3Department of Public Health, Dietetics and Lifestyle Disorders, Faculty of Medicine, University of Information Technology and Management in Rzeszow, Rzeszow, Poland.
4Department of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology of National Academy of Sciences of Ukraine, Kiev, Ukraine.
5Department of Pharmaceutical Chemistry, Vinnytsia National Pyrogov Memorial Medical University, Vinnytsia, Ukraine.
6Department of Quality, Standardisation and Certification of Drugs, National University of Pharmacy, Kharkiv, Ukraine.
7Department of Pharmaceutical Chemistry, National University of Pharmacy, Kharkiv, Ukraine.

ARTICLE INFO

Received on: 07/11/2019
Accepted on: 17/04/2020
Available online: 04/07/2020

Key words:
Anti-cancer activity, Iridaceae, dry extracts.

ABSTRACT

The different effects on human tumor cells (MCF-7, HepG2, HCT116, HeLa, HL-60, and HaCaT) for Ukrainian plant extracts have been examined for the first time. The extracts were from Crocus sativus (stigma, flowers, leaves, and corms), Juno bucharica (leaves), Gladiolus hybrid Zefir (leaves), and Iris hungarica (rhizomes) from Iridaceae family. All the studied extracts exhibited in vitro dose- and time-dependent killing capabilities on applied tumor cell lines. Their killing activity was tissue specific toward tumor cells. The HL-60 acute promyelocytic leukemia cell line and HCT116 colon adenocarcinoma cell line were found as the most sensitive toward treatment with studied plant extracts. It was found that the extracts were not active against normal human epidermal keratinocytes of the HaCaT line. Gladiolus leaf extract showed particularly strong anticancer properties in vitro. The current results for the first time suggest that Iridaceae plant water dry extracts are promising anticancer reagents. Subsequently, the results can be used to develop a prevention agent for the treatment of human cancers.

INTRODUCTION

According to the World Health Organization (WHO) (Cancer WHO, 2019; Lang-Schwarz et al., 2019), cancer today is one of the major causes of death among the world's population; in 2018, the number of deaths was 9.6 million people. Recently, the new methods of treating oncological diseases have appeared (nanotherapy, neutron capture, and low-intensity electrosresonance therapy), and besides, classical methods are used – chemotherapy, surgery, and radiation therapy. However, all of the above methods are accompanied by a number of side effects, which also negatively affect the patient's health. Therefore, the development of the cancer drugs from the plant materials and their use in the clinical practice are still today an urgent task (Desai et al., 2008; Sawadogo et al., 2012; Wang et al., 2019). More than 60% of drugs based on the natural products or herbal raw material are currently used for the treatment of cancer (Majolo et al., 2019; Solowey et al., 2014). The recent scientific studies show that various food plants, medicinal plants, and spices contain the primary and secondary metabolites that help in the treatment of cancer (Asowata-Ayodele et al., 2016; Deng et al., 2002). A study of the pharmacological activity of the plant extracts and their biologically active components, namely, piperine, curcumin, thymoquinone, crocin, capsaicin, oenothein B (Li et al., 2018; Zheng et al., 2016), polysaccharides (Ma et al., 2019), polyphenols (Wang et al., 2019), and other bioactive metabolites (Bobach et al., 2014), has demonstrated their anticancer, antibacterial, anti-inflammatory, antioxidant, and immunomodulatory effects. The presence of the above activities ensures the effectiveness of the prevention and treatment of different cancer types such as lung, stomach, skin, breast, cervix, liver, and prostate cancers. Currently, more than 3,000 plants worldwide have anticancer properties. From the scientific...
viewpoint, the idea of the anticancer herbal raw materials searching is not new, but for the correct user, the detailed phytochemical and pharmacological studies are always necessary. Thus, the present research results undoubtedly provide new knowledge about the anticancer effect of different dry extracts of plants from Iridaceae family (Crocus, Iris, Gladiolus, and Juno genus) of Ukrainian flora.

The diverse study of Iridaceae plants indicates their potential as anticancer agents. The phytochemical research of Iridaceae plants has shown the presence of the phenolic compounds (isoflavones, flavonoids, flavanones, xanthones, and hydroxycinnamic acids) (Mykhailenko et al., 2019; Singab et al., 2016) as well as polysaccharides and amino acids (Mykhailenko et al., 2020), which possess the presence of the anti-proliferative activity (Alireza et al., 2016; Asif et al., 2013; Gohari et al., 2013; Xie et al., 2014). Different plant extracts and biological active compounds of Iridaceae members have shown different pharmacological activities such as diuretic, anti-inflammatory, antiradical (Jadouali et al., 2019), hepatoprotective, antidepressant, and hypolipidemic activities (Basgedik et al., 2014; Munyemana et al., 2013; Shinwari and Rao, 2018; Singab et al., 2016) as well as immunomodulating, antimitogenic (Kuete et al., 2013; Samarghandian and Borji, 2014), antibacterial (Ayoub et al., 2014), and antitumor activities (Mykhailenko et al., 2019; Wollenweber et al., 2003; Xie et al., 2014). To the best of our knowledge, those plants have not been studied for anticancer activity on leukemia and carcinoma cells in vitro. There are a large number of articles on the antitumor potential of the individual components of Crocus sativus, such as crocin, crocetin, safranal, and picrocrocin; besides, publications on the proliferative activity of an extract from C. sativus stigma (safron) are presented (Samarghandian and Borji, 2014). However, the effect of C. sativus extracts (stigma, leaves, roots, and flowers) on the presented in vitro cell lines (MCF-7, HepG2, HCT116, HeLa, HL-60, and HaCaT) was not evaluated. A study of the pharmacological potential of Gladiolus and Juno plants has never been done. The present study is aimed to preliminarily evaluate the anticancer potential activities against six cancer cell lines of the different tissue origin and against non-tumor cells in vitro.

MATERIALS AND METHODS

Plant material

Juno bucharica (Foster) Vved. leaves (a voucher specimen CUW0056539) and Gladiolus hybrid Zefir leaves (a voucher specimen CUW0056538) as well as Iris hungarica Walst. et Kit. rhizomes (a voucher specimen CUW0056534) were harvested from the collection of botanical gardens of V.N. Karazin Kharkiv National University (Kharkiv, Ukraine) in May 2017. C. sativus stigmas, flowers, leaves, and corms were collected from the plantation in the village Lyubymivka (Ukraine) in November 2017 (a voucher specimen CUW0056541-CUW005654). All voucher specimens were verified by Dr. Gamulya and saved at the Herbarium of V.M. Karazin Kharkiv National University, Kharkiv, Ukraine. Fresh plant material was air-dried and crushed.

Preparation of extracts

The ground plant material of Juno leaves, Gladiolus leaves, Crocus leaves, flowers, and corms, and Iris rhizome (100 g each) was extracted with distilled water (1 l), on a water bath for 2 hours for three times. These extracts were cooled and filtered. The extracts were first concentrated using Rotavapor and then completely dried in a drying cabinet and preserved at 4°C until further use. Crocus stigma powder (5 g) was poured with hot distilled water (500 ml, 80°C) and infused in a dark place for 24 hours. The resulting extract was drained, and the rest of the raw material was refilled with 500 ml of distilled water and left to maceration for another 24 hours at 4°C. Maceration repeated one more time in the same conditions. The obtained extracts were combined, filtered, and dried in a rotary evaporation apparatus at 80°C. The powders were stored in airtight containers at 4°C for further use.

MTT assay

The antineoplastic activity of plant extracts was established by the MTT test (EZ4U, Biomedica, Austria) (Finiuk et al., 2017) on different tissue origin cell lines. For the experiment, the cells were plated in 96-well plates of 100 μl at the concentrations of 5,000 cells/well (substrate-dependent cells) or 10,000–15,000 cells/well (suspension cells) overnight. Then, aliquots of 100 μl of experimental extracts (0, 1, 10, and 100 μg/ml) as well as the reference compound doxorubicin (0, 1, and 10 μg/ml) in culture medium were added to the cells and incubated for the next 72 hours. Furthermore, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT reagent) was appended to the cells following the manufacture recommendations (Biomedica, Austria). The results of the reaction were determined by an Absorbance Reader Bio Tek ELx800 (BioTek Instruments, Inc., Winooski, VT) at 490 and 630 nm. The relative number of living cells (parts per unit) was determined by the ratio of optical densities measured for the wells with tested compounds to the wells with control (non-treated) cells. The half-maximal inhibitory concentration (IC₅₀) of tested extracts was calculated as the extract concentration that reduced the cell viability to 50%. Doxorubicin (Actavis, Romania) was chosen as a reference drug as a positive control. The extracts were added to the cultured cells at the indicated concentrations (0–100 μg/ml) and then were treated for 72 hours. The results were analyzed and illustrated using GraphPad Prism 6 software (GraphPad Software., San Jose, CA). The obtained data are presented as the average ± standard deviation (SD) of three replications in two parallels (n = 6).

Cell culture

Collection sample of HL-60 human myeloid leukemia cells (acute promyelocytic leukemia) was obtained from the Institute of Cancer Research at Vienna Medical University (Vienna, Austria). HepG2 human hepatocarcinoma cells (liver hepatocellular carcinoma), HCT116 human colon carcinoma cells (human colorectal carcinoma), and the collected sample of HaCaT human cell (normal human epidermal keratinocytes) were received from the Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (Kyiv, Ukraine). Collection samples of HeLa human cervix adenocarcinoma cells (cervical adenocarcinoma) and MCF-7 human breast adenocarcinoma cells (Michigan Cancer Foundation-7) were received from the R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology (Kyiv, Ukraine). All cells were grown in RPMI-1640 or Dulbecco’s Modified Eagle’s Medium culture supplemented with 10% fetal bovine serum (all from BioWest, France). Cells were cultivated at 37°C in an atmosphere of 5% CO₂.
RESULTS AND DISCUSSION

An in vitro screening was performed by the MTT assay of the anticancer activity of Iridaceae dry extracts toward the following cell lines: MCF-7 human breast adenocarcinoma cells, HCT116 human colon adenocarcinoma cells, HeLa cervical adenocarcinoma cells, HepG2 hepatocellular carcinoma cells, HL-60 acute promyelocytic leukemia cells, and HaCaT normal human epidermal keratinocytes cells was performed by the MTT assay. The results of the analysis were expressed as IC\textsubscript{50} and shown in Table 1. The Iridaceae extracts have shown different antiproliferative activities. Compared to the doxorubicin, reference drug, the activity of those extracts was lower; however, some extracts had a micromolar value of the IC\textsubscript{50} (Fig. 1).

The obtained data showed that the human acute promyelocytic leukemia cells of HL-60 line were the most sensitive to the action of all the studied plant extracts. The dry Gladiolus leaf extracts (Table 1 and Fig. 1) had the highest toxicity toward leukemia cells with the IC\textsubscript{50} value of 0.5 µg/ml. Juno leaf extracts and Iris rhizome extract demonstrated similar anticancer activity with the IC\textsubscript{50} of 3.5 and 3.6 µg/ml, respectively. The IC\textsubscript{50} value for Crocus corms extract was 7.4 µg/ml. The extracts of Crocus stigma, flowers, and leaves did not attain the IC\textsubscript{50} value even at 100 µg/ml. Previously, the antitumor effect of crocin from Crocus stigma on human leukemia cells of HL-60 was studied but not for the whole extract and not to myeloid leukemia cell line (Sun et al., 2013). Thus, the potential anticancer activity of Iridaceae extracts on leukemia cells of HL-60 line can be placed in the following row: Gladiolus leaves > Juno leaves = Iris rhizome > Crocus corms.

Human colon adenocarcinoma cells of HCT116 line were also sensitive to the activity of plant extracts. The IC\textsubscript{50} for Gladiolus leaf extract was 9.4 µg/ml, for Iris rhizome was 42.3 µg/ml, for Crocus corms was 74.6 µg/ml, and for Crocus stigma was 94.8 µg/ml. It was reported about the effect of saffron extract (0.2–1 mg/ml) in HCT116 colorectal cancer cells (Bukhari et al., 2018), but this work includes only Crocus stigma extract. According to the results of the study, the IC\textsubscript{50} values for stigma extract ranged between 0.58 and 0.98 mg/ml. It should be noted that the composition of the active components of the raw material has a direct effect on the activity of the extracts (Mykhailenko et al., 2020). Moreover, the component composition may vary

Table 1. Antiproliferative activity of tested extracts, IC\textsubscript{50}, µg/ml.

<table>
<thead>
<tr>
<th>No</th>
<th>Dry extract</th>
<th>MCF-7</th>
<th>HCT116</th>
<th>HeLa</th>
<th>HepG2</th>
<th>HL-60</th>
<th>HaCaT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Gladiolus leaves</td>
<td>&gt;100</td>
<td>9.4</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>0.50</td>
<td>&gt;100</td>
</tr>
<tr>
<td>2</td>
<td>Juno leaves</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>3</td>
<td>Iris rhizome</td>
<td>&gt;100</td>
<td>42.3</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>3.6</td>
<td>&gt;100</td>
</tr>
<tr>
<td>4</td>
<td>Crocus stigma</td>
<td>&gt;100</td>
<td>94.8</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>5</td>
<td>Crocus corms</td>
<td>&gt;100</td>
<td>74.6</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>7.4</td>
<td>&gt;100</td>
</tr>
<tr>
<td>6</td>
<td>Crocus flowers</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>7</td>
<td>Crocus leaves</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td></td>
<td>Dox</td>
<td>0.51</td>
<td>0.79</td>
<td>0.21</td>
<td>0.34</td>
<td>0.11</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Figure 1. Cytotoxicity of all tested dry extracts toward different cell lines. After a total experimental time (72 hours), cell vitality was detected by the MTT assay. 1—Gladiolus leaf extract; 2—Juno leaf extract; 3—Iris rhizome extract; 4—Crocus stigma extract; 5—Crocus corm extract; 6—Crocus flower extract; 7—Crocus leaf extract.
depending on the location of the plant cultivation (Ramakrishna and Ravishankar, 2011). This is probably why saffron stigma extract from Ukraine has a slightly higher activity than the extract from Kashmir (Bukhari et al., 2018). The extracts of Juno leaves and Crocus flowers and leaves did not attain the IC_{50} value even at 100 μg/ml (Table 1 and Fig. 1). In this case, the most active sample was also Gladiolus leaf extract.

_Iris_ rhizome extract demonstrated toxicity toward human cervical adenocarcinoma of HeLa line with the IC_{50} of 78.7 μg/ml. Other studied plant extracts were not toxic to HeLa cells (Table 1 and Fig. 1). MCF-7 human breast adenocarcinoma cells and HepG2 human hepatocellular carcinoma cells showed the weakest sensitivity to the extracts of the studied plants. The tested extracts did not have an IC_{50} value of 100 μg/ml. Doxorubicin showed a higher cytotoxic effect toward all studied cell lines if compared to the activity of plant extract.

It should be noted that the studied plants’ extracts were not toxic to normal human epidermal keratinocytes of HaCaT line. The maximal inhibition of the growth of HaCaT cells equaled 28.6% at the action of Crocus corms extract and minimal at the action of Juno leaf extract (Table 1 and Fig. 1). The IC_{50} value of doxorubicin for HaCaT cells was 0.7 μg/ml. Thus, Gladiolus leaf and _Iris_ rhizome extracts demonstrated the highest cytotoxic effect toward the HL-60 human acute promyelocytic leukemia cells and HCT116 colon adenocarcinoma cells. Previously, for _C. sativus_ flower acetone extract (50–200 μg/ml), the concentration-dependent activity on HaCaT cells was established (Verjee et al., 2017). However, the acetone flower extract has a more toxic solvent than the aqueous extract. In the following studies, we need to increase the dose of _Iridaceae_ plant extract and repeat the experiment, as other authors also take a pre-high concentration of plant extract.

In the current investigation, several species of _Iridaceae_ genus plants have been tested for their anticancer and cytotoxic activity. Kuete et al. (2013) evaluated the cytotoxicity of the methanol extract of _Gladiolus quartinianus_ (40 g/ml) against CCRF-CEM leukemia cells, which exhibited the lowest IC_{50} values below 30 μg/ml. Besides, the induction of apoptosis in CCRF-CEM cells with the loss of mitochondrial membrane potential for _G. quartinianus_ extract was found. The methanol extract of _Iris kashmiriana_ rhizome (400 mg/ml) showed a potent cytotoxic effect against A549 human epithelial cancer cell lines and Caco-2 epithelial cell lines with IC_{50} of 128 and 237 mg/ml, respectively (Asif et al., 2013). Sánchez-Vioque et al. (2016) studied the antiproliferative effect of ethanol extracts from _C. sativus_ corms, flowers, and leaves on human colon adenocarcinoma cells (Caco-2). From their results, the extract of the flower and leaves (ED_{50} 0.42 mg/ml) greatly inhibited the activity of Caco-2 cells. In other investigations, _C. sativus_ stigma aqueous extract inhibited cancer progression dose dependently in doses of 100, 150, and 175 mg/kg (Bathiae et al., 2013). Previously, Parizadeh et al. (2011) isolated a glycoconjugate from saffron corms, for which cytotoxic activity in relation to the HepG2 hepatocellular carcinoma cell line and Hep-2 laryngeal carcinoma cell line was also established. Another study found the cytotoxic effects of crocin on HeLa and MCF-7 cell lines (Mousavi et al., 2011). However, the presented studies relate mainly to the individual compounds from _C. sativus_ and its stigma.

For the first time, the anticancer activity of _J. bucharica_ leaves, _G. hybrid_ Zefir leaves, _I. hungarica_ rhizomes as well as _C. sativus_ raw material extracts was investigated on MCF-7 human breast cancer cell line, HepG2 human hepatocellular carcinoma cell line, HCT116 human colon adenocarcinoma cell line, HeLa cervical adenocarcinoma cell line, HL-60 acute promyelocytic leukemia cells line, and HaCaT normal human epidermal keratinocyte cell line. Thus, the results show the potential of _Iridaceae_ plants for the treatment of cancer, but further research is still needed.

**CONCLUSION**

In folk and clinical medicine of different countries, plants have always played an important role in the treatment and prevention of cancer and other diseases. Moreover, natural components from plants at the level of synthetic compounds are used in the creation of new drugs. _Plants of Iridaceae_ family ( _J. bucharica_, _G. hybrid_ Zefir, _I. hungarica_, and _C. sativus_) are herbaceous plants traditionally used in folk medicines of European countries as antitumor, anti-inflammatory, anticonvulsant, analgesic, antioxidative activity, antipyretic, etc. _Gladiolus_ leaf extract showed particularly strong anticancer properties in vitro toward human leukemia and colon adenocarcinoma cells in MTT assay. _Iris_ rhizome dry extracts have shown lower activity on human cervical adenocarcinoma cells. These plant extracts have demonstrated low toxicity toward normal human epidermal keratinocytes of HaCaT line. The studies on establishing the action mechanism of the investigated extracts will be continued. These herbal extracts have shown their potential anticancer activity in vitro studies that can be used for further drug creation for the prevention and treatment of leukemia, colon, and cervix cancers. This is the first investigation about the anticancer activity of _Iridaceae_ plant extracts.

**ACKNOWLEDGMENT**

The authors would like to gratitude to Dr. Orlova (Botanical garden of the Kharkiv National University named after V.N. Karazin, Kharkiv, Ukraine) for help in determining the systematic belonging of plants.

**CONFLICT OF INTEREST**

The authors declared that they have no conflicts of interest.

**FINANCIAL SUPPORT**

None.

**REFERENCES**


How to cite this article: